BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250805
DTEND;VALUE=DATE:20250808
DTSTAMP:20260515T052926
CREATED:20250328T115942Z
LAST-MODIFIED:20250404T112846Z
UID:40784-1754352000-1754611199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences East
DESCRIPTION:Join us this August in Boston\, MA for the 9th LEAP HR: Life Sciences East. \nConnect with 200+ leadership professionals in biopharma dedicated to attracting\, retaining and developing critical talent to deliver their organizations mission. Engage with HR leaders who are also navigating a period of uncertainty amongst: regulation changes\, financial uncertainties\, supply chain disruptions\, and changing workforce dynamics. Leave with a ready-made support network of industry peers committed to building high-performing organizations. \nExplore 40+ case studies from leading drug development organizations on shifting to new systems of empowered teams\, accelerating the development of both current and future leaders\, and optimizing global team dynamics across diverse business layers. \nFind out more now: https://ter.li/v3bct4
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-east-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250819
DTEND;VALUE=DATE:20250822
DTSTAMP:20260515T052926
CREATED:20250425T132731Z
LAST-MODIFIED:20250425T132731Z
UID:40998-1755561600-1755820799@www.pharmajournalist.com
SUMMARY:3rd ADC Linker & Conjugation Summit
DESCRIPTION:As dual-payload and novel MoA payload ADCs continue to reshape the therapeutic landscape\, the 3rd ADC Linker & Conjugation Summit returns as the definitive forum for ADC chemists and bioconjugation specialists aiming to overcome persistent challenges in hydrophobicity\, aggregation\, and linker stability. \nThis three-day technical deep dive is your chance to: \n\nDiscover next-generation conjugation strategies and site-specific technologies\nTackle the unique challenges of dual-payload and novel payload ADCs\nBenchmark cutting-edge solutions for improved DAR control and linker stability\nAdvance ADC reproducibility and performance with chemistries beyond maleimide\n\nJoin 80+ industry experts\, including ADC chemists\, biotech innovators\, and service providers\, all focused on refining ADC design for enhanced PK profiles and safety. \nExplore the brand-new event guide and be part of the community driving the next wave of ADC innovation. https://ter.li/387nz1
URL:http://www.pharmajournalist.com/event/3rd-adc-linker-conjugation-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250819
DTEND;VALUE=DATE:20250822
DTSTAMP:20260515T052926
CREATED:20250509T085540Z
LAST-MODIFIED:20250509T085540Z
UID:41058-1755561600-1755820799@www.pharmajournalist.com
SUMMARY:9th IPF Summit
DESCRIPTION:This August\, the 9th IPF Summit returns as the industry’s must attend summit\, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks\, to shape the future of pulmonary fibrosis drug development. \nBe one of the first to view the agenda here: https://ter.li/moky9n \nA Snapshot of What Awaits You in 2025: \n\nCase Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success\nBrand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos\nNavigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves\, with input from Boehringer Ingelheim\, BMS\, and Insilico Medicine\nEnhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025\, featuring case studies from GSK\, Boehringer Ingelheim\, and others.\n\nIf ever there was a time to invest in this community and a conference\, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster. \nFind all the information needed here: https://ter.li/moky9n
URL:http://www.pharmajournalist.com/event/9th-ipf-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250827
DTEND;VALUE=DATE:20250830
DTSTAMP:20260515T052926
CREATED:20250513T120710Z
LAST-MODIFIED:20250513T120710Z
UID:41063-1756252800-1756511999@www.pharmajournalist.com
SUMMARY:5th Oligonucleotides for CNS Summit
DESCRIPTION:In a year where neurology has overtaken cancer as the number one indication prioritized by oligonucleotide drug developers\, now is the time to stay at forefront of ASO and siRNA innovation. Returning to Boston\, this August\, the 5th Oligonucleotides for CNS Summit unites 100+ biopharma leaders across RNA biology\, oligonucleotide chemistry\, DMPK\, pharmacology\, and platform technology\, to discover the latest advancements in brain delivery\, chemistry\, nonclinical safety and more! \nJoin your peers Alnylam Pharmaceuticals\, Denali Therapeutics\, Genentech\, FDA\, Novo Nordisk\, Regeneron\, Servier\, Stoke Therapeutics\, Ultragenyx Pharmaceutical and more\, to overcome key challenges\, build cross-modality relations\, unpack the latest clinical data and redefine the landscape of oligonucleotide research. \nWhat to Expect: \n\nBenchmark your chemistry and biology innovations with dual-tracked workshops developed for medicinal chemists and neurobiologists\nHear from 10+ new speakers\, including insights from the FDA and companies breaking ground across neuromuscular\, neurodegenerative\, neurodevelopmental and ultra-rare indications\nExplore the next wave of delivery tech\, from TfR1 and AOCs to computational CNS PK/PD modeling and novel RNA editing approaches\n\nCapitalize on the recent ‘oligonucleotide boom\,’ by attending this meeting! \nTo know more visit: https://ter.li/uw2usc
URL:http://www.pharmajournalist.com/event/5th-oligonucleotides-for-cns-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR